Evidence map›Paper›PMID 36012646›Full record

ArticleInternational journal of molecular sciences2022

Drug-Loaded Polymeric Micelles Based on Smart Biocompatible Graft Copolymers with Potential Applications for the Treatment of Glaucoma.

Manuela-Ramona Blanaru Ozturk, Marcel Popa, Delia Mihaela Rata, Anca Niculina Cadinoiu, Frederique Parfait, Christelle Delaite, Leonard Ionut Atanase, Carmen Solcan, Oana Maria Daraba

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024
    Review
  11. Article
  12. Review
  13. Biopolymers for Enhanced Health Benefits.International journal of molecular sciences · 2023
    Article
  14. Review
  15. Recent development of polymer nanomicelles in the treatment of eye diseases.Frontiers in bioengineering and biotechnology · 2023
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Manuela-Ramona Blanaru OzturkFaculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Marcel Popa"Cristofor Simionescu" Faculty of Chemical Engineering and Environmental Protection, "Gheorghe Asachi" Technical University of Iasi, 700050 Iasi, Romania.ORCID 0000-0003-4929-0830
Delia Mihaela RataFaculty of Medical Dentistry, "Apollonia" University of Iasi, 700511 Iasi, Romania.ORCID 0000-0002-4917-9406
Anca Niculina CadinoiuFaculty of Medical Dentistry, "Apollonia" University of Iasi, 700511 Iasi, Romania.ORCID 0000-0002-3708-3992
Frederique ParfaitLPIM, Université de Haute Alsace, 68100 Mulhouse, France.ORCID 0000-0003-0445-6382
Christelle DelaiteLPIM, Université de Haute Alsace, 68100 Mulhouse, France.
Leonard Ionut AtanaseAcademy of Romanian Scientists, 050045 Bucharest, Romania.ORCID 0000-0002-3657-1492
Carmen SolcanPublic Health Department, Faculty of Veterinary Medicine, "Ion Ionescu de la Brad" University of Life Sciences, 700490 Iasi, Romania.
Oana Maria DarabaFaculty of Medical Dentistry, "Apollonia" University of Iasi, 700511 Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is the second leading cause of blindness in the world. Despite the fact that many treatments are currently available for eye diseases, the key issue that arises is the administration of drugs for long periods of time and the increased risk of inflammation, but also the high cost of eye surgery. Consequently, numerous daily administrations are required, which reduce patient compliance, and even in these conditions, the treatment of eye disease is too ineffective. Micellar polymers are core-shell nanoparticles formed by the self-assembly of block or graft copolymers in selective solvents. In the present study, polymeric micelles (PMs) were obtained by dialysis from smart biocompatible poly(ε-caprolactone)-poly(N-vinylcaprolactam-co-N-vinylpyrrolidone) [PCL-g-P(NVCL-co-NVP)] graft copolymers. Two copolymers with different molar masses were studied, and a good correlation was noted between the micellar sizes and the total degree of polymerisation (DPn) of the copolymers. The micelles formed by Cop A [PCL120-g-P(NVCL507-co-NVP128)], with the lowest total DPn, have a Z-average value of 39 nm, whereas the micellar sizes for Cop B [PCL120-g-P(NVCL1253-co-NVP139)] are around 47 nm. These PMs were further used for the encapsulation of two drugs with applications for the treatment of eye diseases. After the encapsulation of Dorzolamide, a slight increase in micellar sizes was noted, whereas the encapsulation of Indomethacin led to a decrease in these sizes. Using dynamic light scattering, it was proved that both free and drug-loaded PMs are stable for 30 days of storage at 4 °C. Moreover, in vitro biological tests demonstrated that the obtained PMs are both haemo- and cytocompatible and thus can be used for further in vivo tests. The designed micellar system proved its ability to release the encapsulated drugs in vitro, and the results obtained were validated by in vivo tests carried out on experimental animals, which proved its high effectiveness in reducing intraocular pressure.

Indexed as

GlaucomaMicellesAnimalsDrug CarriersPolyestersPolyethylene GlycolsPolymersRenal DialysisDrug CarriersMicellesPolyestersPolyethylene GlycolsPolymerscytotoxicitydorzolamideglaucomahaemolysisindomethacinintraocular pressurein vivo testspolymeric micelles

Identifiers

PMID36012646
PMCPMC9409108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.